

## MRFF submission: Genomics Health Futures Mission's

### **Are the priority areas for investment identified in the refreshed Implementation Plan the most effective way for delivering on the Genomics Health Futures Mission's goal and aims?**

InGeNA supports the refreshed Implementation Plan's priorities as a foundation for the Genomics Health Futures Mission's goals. We believe that to truly impact patient outcomes, the focus must be on mainstreaming genomics as part of standard care across Australia. Prioritising rare diseases, cancer, and chronic conditions is essential, but achieving this requires coordinated investment in workforce development, data infrastructure, and ethical, equitable access.

Collaboration across industry, government, and research sectors will be key to realising these goals, ensuring genomic advances are rapidly translated into accessible, everyday healthcare.

### **Are there existing research activities which could be utilised to contribute to the Genomics Health Futures Mission refreshed Roadmap and/or Implementation Plan aims and priority areas for investment? How can these be leveraged?**

InGeNA acknowledges that existing research in rare disease genomics, cancer genomics, and pharmacogenomics aligns with the Genomics Health Futures Mission's aims. The MRFF can play a pivotal role in leveraging these activities by addressing key bottlenecks, particularly within the regulatory system and healthcare integration. Supporting initiatives that streamline regulatory pathways and enable smoother adoption into clinical practice will accelerate mainstreaming of genomics as standard care. Focused MRFF investment can enhance data sharing, workforce development, and equitable access frameworks, maximizing the impact of existing research and fostering sustainable genomics integration across Australia's healthcare system.

### **Are the 'Evaluation approach and measures' appropriate for assessing and monitoring progress towards the Genomics Health Futures Mission's goal and aims?**

InGeNA supports the Genomics Health Futures Mission's evaluation approach but recommends additional emphasis on metrics that capture real-world impact and equitable access. While the current measures assess research outputs and clinical translation, adding indicators for patient outcomes, healthcare system integration, and economic value would provide a more comprehensive view of progress. Evaluating cross-sector collaborations and partnerships would also reflect the broader ecosystem's role in advancing genomics. To ensure inclusivity, metrics that assess reach among diverse populations are critical. These adjustments would strengthen the mission's capacity to monitor meaningful, sustainable progress.



Your response has been submitted

Your response ID is ANON-ZXFK-BTPB-B. Please have this ID available if you need to contact us about your response.

A receipt for your response has been emailed to you from the address **no-reply@mail1.citizenspace.com** with the subject "**Response received - Response ID: ANON-ZXFK-BTPB-B**". If it doesn't appear in your inbox within a couple of minutes, please check your "spam" or "junk" folder.

Thank you for your response.